Answers are grounded in this paper and cite their sources.
The advent in catalysis of enantiopure (N and/or O)P‐monodentate, bis(N and/or O)P‐, and (N and/or O)P,P‐bidentate ligands is recounted. In particular, their transition‐metal‐complex‐enabled enantioselective CC hydrogenation of archetypal β‐amido β‐(alkyl or aryl)‐vinylcarboxylic esters, phosphonates, and phosphine oxide analogs is reviewed. The efficient P‐ligands are juxtaposed with their reported attained enantioselectivity per substrate alongside the screening conditions. Additional literature pertaining to the asymmetric hydrogenation of the said phosphonates, employing enantiopure diphosphine ligands, is included.
No takes yet. Share an insight, caveat, or question.
Jeran et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: